Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study

Gustave Roussy, Cancer Campus, Grand Paris1 site in 1 country11 target enrollmentNovember 25, 2017

ConditionsNSCLC

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: NSCLC
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Enrollment: 11
Locations: 1
Primary Endpoint: Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.
Status: Terminated
Last Updated: last month

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).

Registry

clinicaltrials.gov

Start Date

November 25, 2017

End Date

August 29, 2019

Last Updated

last month

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (\</=5 mestastasis, \</= 3 organ reached)
•Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts)
•Signed consent
•Patients affiliated with the social security scheme or beneficiary of a similar scheme.

Exclusion Criteria

•Pregnant / lactating woman
•Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent
•Previous cancer in the 2 years prior to registration
•Previousradiotherapy / thoracic surgery
•Patients under experimental treatment or for whom the administration of an experimental treatment is planned
•Claustrophobic patients
•Severe Renal Insufficiency (Clearance MDRD Cockroft \<30ml / min)
•Uncontrolled diabetes, hyperglycemia\> 1.8g / L
•Patient with metallic implants not compatible with MRI or any immovable implanted electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)